Neuroblastoma Treatment Market by Key Players, Regions, Company Profile, Growth Opportunity, and Challenges by 2030
Neuroblastoma Market Highlights
According
to the American Society of Clinical Oncology (ASCO) April 2018 publication,
every year, more than 700 children get diagnosed with neuroblastoma in the US
and it is also indicated that neuroblastoma is the most common cancer in children younger than 1 year. It is more
commonly found in boys compare to girls. The increasing cases of childhood
cancer boost market growth during the forecast period.
The Neuroblastoma Market is projected to reach USD 470.81 Million by 2030 at 3.40% CAGR during
the forecast period 2022-2030. Neuroblastoma is a childhood cancer most
commonly occurs in children below the age of 5 years. The neuroblast may cause
due to the immature cell growth or mutation in the gene responsible for
controlling cell proliferation. The increasing cases of childhood cancer,
rising research on neuroblastoma treatment and increasing spending on cancer
treatment is expected to drive market growth over the forecast period.
Despite
the drivers, shortage of trained healthcare specialists and the high cost of
this therapy can restrain the market growth over the assessment period.
Segmentation
The
global neuroblastoma market has been segmented into diagnostics, treatment, and
end user.
The
market, based on diagnostics, has been segmented into various tests, MIBG scan,
imaging, and biopsy. The tests are further sub-segmented into bone marrow,
tissue, urine, and blood.
The
market, by treatment, has been segmented into surgery, chemotherapy, radiation
therapy, stem cell transplant, immunotherapy, and monoclonal antibody
treatment.
Based
on end user, the global neuroblastoma market report has been segmented into hospitals ambulatory surgical centres,
diagnostic canters, research centres, and others.
Regional
Analysis
Geographically,
the Americas is expected to dominate the global neuroblastoma market owing to
the presence of well-developed healthcare sector, rising prevalence of infant
cancer cases, and growing expenditure for the healthcare sector. Europe is
expected to hold the second largest position in the global neuroblastoma market
owing to the growing number of child healthcare canters for cancer treatment
and raising awareness about the treatment for neuroblastoma. According to
the Cancer Research UK May 2018 publication, around 100 infants are detected
with neuroblastoma every year in the UK. This provides favourable backgrounds
for the neuroblastoma market to grow.
Asia-Pacific
is expected to be the fastest growing market owing to the increasing children
cancer base and increasing developments in the healthcare segment.
According
to the Neuroblastoma Australia organization October 2018 article, every year
approximately 40 cases of neuroblastoma are indicated in Australia due to some
unknown genetic problems which will support the market growth.
Furthermore,
the Middle Eastern and African region is expected to account for the least
market share in the global market.
Neuroblastoma Treatment Market Players
The global neuroblastoma market players are United
Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer
Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc.,
About Market
Research Future:
At Market Research
Future (MRFR), we enable our customers to unravel the complexity of various
industries through our Cooked Research Report (CRR), Half-Cooked Research
Reports (HCRR), & Consulting Services. MRFR team have supreme objective to
provide the optimum quality market research and intelligence services to our
clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New York
10013
United States of
America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment